脂微球前列地尔联合依达拉奉治疗急性脑梗死疗效探讨

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (511 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要目的探讨脂微球前列地尔联合依达拉奉治疗急性脑梗死的疗效。方法选择2014-06至2016-06住院急性脑梗死患者60例,随机分为联合组(脂微球前列地尔+依达拉奉)和对照组(单用依达拉奉),各30例,全部患者于治疗前、治疗第3天、第7天和第14天行NIHSS评分并检测血清S100B蛋白水平。比较两组患者不同时段NIHSS评分及血清S100B蛋白水平变化。结果治疗后第3天、第7天和第14天联合组NIHSS评分及血清S100B蛋白水平均较对照组为低,差异有统计学意义(P<0.01)。对照组2例为进展性脑梗死,无一例不良反应;联合组1例为进展性脑梗死,2例出现头痛,1例出现面红,轻微肿胀感,未影响治疗。结论脂微球前列地尔联合依达拉奉治疗可改善急性脑梗死患者的临床疗效,减轻脑损伤程度。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	安占军
	徐立霞
	曹洁玮

关键词 ：急性脑梗死, 脂微球前列地尔, 依达拉奉, NIHSS评分, 血清S100B蛋白

Abstract：Objective To investigate the influence of lipid microsphere alprostadil combined with edaravone on the neurological function and serum S100B level of patients with acute cerebral infarction.Methods Between June 2014 and June 2016, sixty patients with acute cerebral infarction were enrolled and randomly and equally divided into the combined group (lipid microsphere alprostadil and edaravone) and the control group (edaravone alone). All the patients received brain MRI examinations(DWI) before treatment, and NIHSS and serum S100B tests before treatment as well as at day 3, 7 and 14 during treatment. The changes of NIHSS and serum S100B levels were compared between the two groups at different time points.Results NIHSS and serum S100B levels of the combined group at day 3, 7 and 14 during treatment were significantly lower than those of the control group(P<0.01). There were two cases of disease progression in the control group, but with no cases of adverse reactions. In the combined group, there was one case of progression, two cases of headache, and one patient who appeared red-faced and felt slightly swollen.Conclusions Lipid microsphere alprostadil combined with edaravone can improve clinical efficacy and alleviate brain damage in patients with acute ischemic stroke.

Key words： acute cerebral infarction lipid microsphere alprostadil edaravone NIHSS serum S100B

收稿日期: 2016-10-03

ZTFLH:

R743.3

作者简介: 安占军,硕士,副主任医师。

引用本文:

安占军,徐立霞,曹洁玮. 脂微球前列地尔联合依达拉奉治疗急性脑梗死疗效探讨[J]. 武警医学, 2017, 28(5): 475-477. AN Zhanjun,XU Lixia,and CAO Jiewei. Influence of lipid microsphere alprostadil combined with edaravone onneurological function and serum S100B level of acute ischemic stroke patients. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(5): 475-477.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2017/V28/I5/475

[1]	全国第四届脑血管病学术委员会. 各类脑血管疾病诊断要点[J].中华神经科杂志, 1996, 29(6): 379-381.
[2]	Khoury R, Jung R, Nanda A, et al. Overview of key factors in improving access to acute stroke care [J]. Neurology, 2012, 79(13): 26-34.
[3]	Wardlaw J M, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke:an updated systematic review and meta-analysis[J]. Lancet, 2012, 379(9834): 2364-2372.
[4]	Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National Stroke Registry (CNSR)[J]. Stroke, 2011, 42(6):1658-1664.
[5]	赵彦超. 前列地尔联合依达拉奉治疗急性脑梗死的疗效观察[J]. 中国实用神经疾病杂志,2015, 18(18):111-113.
[6]	彭晓. 依达拉奉联合前列地尔脂微球注射液治疗急性进展性脑梗死患者临床疗效观察[J]. 现代诊断与治疗, 2015, 2(3): 517-518.
[7]	Shaw G,Marlatt N,Ferguson P,et al.Identification of a dimefic intermediate in the unfolding pathway for the calcium—binding protein S100B[J].Mol Biol,2008,382:1075-1088
[8]	Guglielmo S,Francesca R,Cataldo A,et al.S100B protein in tissue development,repair and regeneration[J].World J Biol Chem,2013,4(1):1-12.
[9]	Nguyen D N,huyghens L,wellens F, et al. Serum S100B protein could help to detect cerebral complications associated with extracorporeal membrane oxygenation (ECMO)[J].Neurocritical Care,2014,20(3):367-374.
[10]	Wadiwala M F,Sonawalla A,Karnal A K.What is the ro1e of free radical scavengers in acute stroke?[J].J Pak Med Assoc, 2012, 62(5):512-513.
[11]	Ren Y,Wei B,Song X,et al.Edaravone’s free radical scavenging mechanisms of neuroprotection against cerebral ischemia:review of the literature[J].Int J Neurosci, 2015, 125(8):555-565.
[12]	Li J H, Yang P, Li A L, et al. Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow [J]. J Zhejiang Univ Sci B,2011,12(8):638-643.
[13]	Dong M F,Ma Z S, Ma S J, et al. Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease [J]. J Cardiovasc Pharmacol Ther, 2012, 17(17):303-307.
[14]	Liu H J, Ma J W, Qiao Z Y, et al. Study of molecular mechanism of prostaglandin E1 in inhibiting coronary heart disease[J]. Mol Biol Rep, 2013, 40(12):6701-6708.
[15]	Liu W J, Ming Q, Shen J Y, et al. Trimetazidine prevention of contrast-induced nephropathy in coronary angiography[J]. Am J Med Sci, 2015, 350(5):398-402.
[16]	Eyuboglu M.Renin-angiotensin-aldosterone-system blochade and contrast-induced nephropaphy [J]. Int J cardiol, 2015, 202(4):196-203.